Seattle Institute For Biomedical And Clinical Research

Alpha Cognition's ZUNVEYL Receives FDA Approval for Alzheimer's Treatment, Set for Q1 2025 Launch

6 months ago

• Alpha Cognition's ZUNVEYL, a novel Alzheimer's disease treatment, has received FDA approval and is slated for commercial launch in Q1 2025. • The company successfully raised $4.5 million in bridge financing to support the commercial supply and preparation for ZUNVEYL's market introduction. • Stability tests have extended ZUNVEYL's shelf life to 24 months, enhancing its commercial viability and market readiness. • Alpha Cognition is focusing on the Long-Term Care market, which accounts for 36% of the 11 million acetylcholinesterase inhibitor prescriptions in the U.S.